Transient stimulatory effects on pituitary-thyroid axis in patients treated with interleukin-2

Thyroid

Volumn 11, Issue 7, 2001, Pages 665-670

  Witzke, Oliver ^a   Winterhagen, Toni ^a   Saller, Bernhard ^a   Roggenbuck, Ulla ^a   Lehr, Iris ^a   Philipp, Thomas ^a   Mann, Klaus ^a   Reinhardt, Walter ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,3',5' TRIIODOTHYRONINE; ALBUMIN; LIOTHYRONINE; RECOMBINANT INTERLEUKIN 2; THYROID PEROXIDASE; THYROTROPIN; THYROXINE; THYROXINE BINDING GLOBULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FREE THYROXINE INDEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHYSIS THYROID SYSTEM; LIOTHYRONINE BLOOD LEVEL; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; MALE; PITUITARY GLAND; PROSPECTIVE STUDIES; THYROID GLAND; THYROTROPIN; THYROXINE; TIME FACTORS; TRIIODOTHYRONINE;

EID: 0034928499     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/105072501750362736     Document Type: Article

References (30)

1. Effect of interleukin-2 on the pool of latently infected, resting CD4 T cells in HIV-1 infected patients receiving highly active antiretroviral therapy
2. Randomised controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients
3. Increases in CD4-T-lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection
4. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
5. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma
6. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
7. Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignancies
8. How immune-based interventions can change HIV therapy
9. Interleukin-2: Inception, impact, and implications
10. Relationship of the increased serum interleukin-6 concentration to changes of thyroid function in nonthyroidal illness
11. Continuous infusion of interleukin-1β induces a nonthyroidal illness syndrome in the rat
12. Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-alpha
13. Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans
14. Immunoneutralization of interleukin-1, tumor necrosis factor, interleukin-6 or interferon does not prevent the LPS-induced sick euthyroid syndrome in mice
15. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-α
16. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone
17. Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma
18. Transient thyrotoxicosis and persistent hypothyroidism due to acute auto-thyroiditis after interleukin-2 and interferon-alpha therapy for metastatic carcinoma: A case report
19. Acute thyroid dysfunction (thyroiditis) after therapy with interleukin-2
20. Unique alterations of thyroid hormone indices in the acquired immunodeficiency syndrome (AIDS)
21. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease
22. Thyroiditis after treatment with interleukin-2 and interferon-alpha-2a
23. Soluble cytokine receptors and the low 3, 5, 3′-triiodothyronine syndrome in patients with nonthyroidal disease
24. Relationship between serum 3, 5, 3′-triiodothyronine and serum interleukin-8 interleukin-10 or interferon-γ in patients with nonthyroidal illness
25. A study of the serum concentration of tumor necrosis factor-alpha in thyroidal and nonthyroidal illnesses
26. Tumor necrosis factor: A putative mediator of the sick euthyroid syndrome in man
27. Anterior pituitary hormone control by interleukin-2
28. Comparison of alterations in circulating thyroglobulin triiodothyronine and thyroxine in response to exogenous (bovine) and endogenous (human) thyrotropin
29. Association between serum interleukin-6 and serum 3, 5, 3′-triiodothyronine in nonthyroidal illness